| Literature DB >> 35744845 |
Valentina Noemi Madia1, Walter Toscanelli2, Daniela De Vita3, Marta De Angelis2, Antonella Messore1, Davide Ialongo1, Luigi Scipione1, Valeria Tudino1, Felicia Diodata D'Auria2, Roberto Di Santo1, Stefania Garzoli4, Annarita Stringaro5, Marisa Colone5, Magda Marchetti6, Fabiana Superti6, Lucia Nencioni2, Roberta Costi1.
Abstract
Influenza viruses are transmitted from human to human via airborne droplets and can be transferred through contaminated environmental surfaces. Some works have demonstrated the efficacy of essential oils (EOs) as antimicrobial and antiviral agents, but most of them examined the liquid phases, which are generally toxic for oral applications. In our study, we describe the antiviral activity of Citrus bergamia, Melaleuca alternifolia, Illicium verum and Eucalyptus globulus vapor EOs against influenza virus type A. In the vapor phase, C. bergamia and M. alternifolia strongly reduced viral cytopathic effect without exerting any cytotoxicity. The E. globulus vapor EO reduced viral infection by 78% with no cytotoxicity, while I. verum was not effective. Furthermore, we characterized the EOs and their vapor phase by the head-space gas chromatography-mass spectrometry technique, observing that the major component found in each liquid EO is the same one of the corresponding vapor phases, with the exception of M. alternifolia. To deepen the mechanism of action, the morphological integrity of virus particles was checked by negative staining transmission electron microscopy, showing that they interfere with the lipid bilayer of the viral envelope, leading to the decomposition of membranes. We speculated that the most abundant components of the vapor EOs might directly interfere with influenza virus envelope structures or mask viral structures important for early steps of viral infection.Entities:
Keywords: Chinese star anise; antivirals; bergamot; essential oil vapors; eucalyptus; influenza A H1N1 virus; tea tree oil
Mesh:
Substances:
Year: 2022 PMID: 35744845 PMCID: PMC9230754 DOI: 10.3390/molecules27123718
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Chemical composition (percentage mean value ± standard deviation) of EOs.
| N° | Component 1 | LRI 2 | LRI 3 | BEO 4
| IV-EO 5
| TTO 6 (%) | EEO 7 (%) |
|---|---|---|---|---|---|---|---|
| 1 | α-thujene | 920 | 923 | 0.3 ± 0.03 | - | - | 1.7 ± 0.02 |
| 2 | α-pinene | 941 | 943 | 1.3 ± 0.02 | 0.3 ± 0.03 | 0.2 ± 0.02 | - |
| 3 | sabinene | 973 | 972 | - | - | tr | - |
| 4 | β-myrcene | 981 | 983 | 1.5 ± 0.03 | tr | 0.1 ± 0.00 | 0.6 ± 0.02 |
| 5 | β-pinene | 988 | 986 | 7.3 ± 0.02 | - | 0.1 ± 0.00 | - |
| 6 | α-phellandrene | 1008 | 1005 | - | 0.2 ± 0.02 | tr | 0.5 ± 0.02 |
| 7 | α-terpinene | 1013 | 1010 | - | - | 1.1 ± 0.02 | - |
| 8 | p-cymene | 1020 | 1016 | 0.7 ± 0.02 | tr | 0.3 ± 0.04 | 1.7 ± 0.01 |
| 9 | limonene | 1021 | 1023 | 31.9 ± 0.06 | 0.1 ± 0.02 | - | - |
| 10 | 1,8-cineole | 1026 | 1025 | - | - | 0.5 ± 0.02 | 93.7 ± 0.02 |
| 11 | cis-β-ocimene | 1035 | 1032 | 0.5 ± 0.02 | - | - | - |
| 12 | β-terpinene | 1040 | 1036 | - | tr | - | - |
| 13 | trans-β-ocimene | 1044 | 1043 | 0.2 ± 0.02 | - | - | - |
| 14 | trans-sabinene hydrate | 1057 | 1053 | - | 0.2 ± 0.02 | - | - |
| 15 | γ-terpinene | 1059 | 1054 | 7.5 ± 0.02 | - | 2.7 ± 0.03 | 1.6 ± 0.02 |
| 16 | cis-sabinene hydrate | 1072 | 1069 | - | tr | - | - |
| 17 | terpinolene | 1079 | 1080 | - | - | tr | tr |
| 18 | linalool | 1090 | 1092 | 17.0 ± 0.03 | 1.0 ± 0.02 | - | - |
| 19 | terpinen-4-ol | 1164 | 1160 | - | - | 92.4 ± 0.03 | tr |
| 20 | estragole | 1180 | 1177 | - | 3.2 ± 0.02 | - | - |
| 21 | α-terpineol | 1185 | 1183 | tr | - | 0.6 ± 0.02 | 0.1 ± 0.00 |
| 22 | carveol | 1210 | 1201 | tr | - | - | - |
| 23 | cis-piperitol | 1219 | 1215 | - | - | tr | -- |
| 24 | p-anisaldehyde | 1232 | 1229 | - | 0.2 ± 0.03 | - | - |
| 25 | linalyl acetate | 1259 | 1252 | 31.4 ± 0.02 | - | - | - |
| 26 | anethole | 1269 | 1260 | - | 93.0 ± 0.07 | - | - |
| 27 | α-citral | 1291 | 1287 | 0.1 ± 0.02 | - | - | - |
| 28 | α-copaene | 1373 | 1370 | - | - | 0.1 ± 0.00 | - |
| 29 | β-elemene | 1410 | 1406 | - | - | tr | - |
| 30 | β-caryophyllene | 1426 | 1424 | - | 0.7 ± 0.03 | 0.1 ± 0.00 | - |
| 31 | α-bergamotene | 1435 | 1430 | - | tr | - | - |
| 32 | aromadendrene | 1459 | 1460 | - | tr | 0.4 ± 0.03 | - |
| 33 | humulene | 1470 | 1465 | - | tr | tr | - |
| 34 | γ-muurolene | 1490 | 1486 | - | - | 0.2 ± 0.02 | - |
| 35 | ledene | 1499 | 1492 | - | - | 0.5 ± 0.02 | - |
| 36 | β-bisabolene | 1501 | 1501 | 0.1 ± 0.02 | tr | - | - |
| 37 | α-farnesene | 1510 | 1506 | 0.1 ± 0.01 | tr | - | - |
| 38 | δ-cadinene | 1528 | 1530 | - | - | 0.4 ± 0.02 | - |
| 39 | spathulenol | 1573 | 1571 | - | - | tr | - |
| 40 | viridiflorol | 1580 | 1583 | - | - | 0.1 ± 0.01 | - |
| 41 | globulol | 1596 | 1594 | - | - | 0.1 ± 0.01 | - |
| 42 | cubenol | 1635 | 1631 | - | - | 0.1 ± 0.01 | - |
| SUM | 99.9 | 98.9 | 100.0 | 99.9 | |||
| Terpenoids | 68.3 | 1.8 | 98.0 | 99.9 | |||
| Sesquiterpenoids | 0.2 | 0.7 | 1.9 | - | |||
| Other | 31.4 | 96.4 | 0.1 | - |
1 The components are reported according to their elution order on apolar column; 2 Linear Retention Indices measured on apolar column; 3 Linear Retention indices from literature; 4 Percentage mean values of C. bergamia liquid phase components; 5 Percentage mean values of I. verum liquid phase components; 6 Percentage mean values of M. alternifolia liquid phase components; 7 Percentage mean values of E. globulus liquid phase components; - Not detected; tr: traces (mean value <0.1%).
Chemical composition of volatiles (percentage mean value ± standard deviation) of EOs.
| N° | Component 1 | LRI 2 | LRI 3 | BEO 4 (%) | IV-EO 5 (%) | TTO 6 (%) | EEO 7 (%) |
|---|---|---|---|---|---|---|---|
| 1 | α-thujene | 920 | 923 | 1.5 ± 0.02 | 0.4 ± 0.02 | 3.5 ± 0.04 | 5.6 ± 0.02 |
| 2 | α-pinene | 941 | 943 | 6.5 ± 0.02 | 19.1 ± 0.06 | 10.0 ± 0.04 | - |
| 3 | camphene | 950 | 946 | 0.3 ± 0.02 | 0.3 ± 0.03 | 0.1 ± 0.00 | - |
| 4 | sabinene | 974 | 972 | - | - | 0.3 ± 0.02 | - |
| 5 | β-myrcene | 981 | 983 | 3.9 ± 0.03 | 2.3 ± 0.04 | 1.5 ± 0.04 | 0.8 ± 0.00 |
| 6 | β-pinene | 988 | 986 | 20.4 ± 0.05 | - | 1.7 ± 0.06 | - |
| 7 | α-phellandrene | 1008 | 1005 | 0.2 ± 0.01 | 5.9 ± 0.07 | 1.4 ± 0.01 | 0.6 ± 0.01 |
| 8 | α-terpinene | 1013 | 1010 | - | - | 18.1 ± 0.02 | - |
| 9 | p-cymene | 1020 | 1016 | 1.1 ± 0.03 | 0.5 ± 0.03 | 10.7 ± 0.04 | 1.9 ± 0.04 |
| 10 | limonene | 1021 | 1023 | 51.2 ± 0.03 | 3.8 ± 0.06 | - | - |
| 11 | 1,8-cineole | 1026 | 1025 | - | - | 8.3 ± 0.03 | 89.8 ± 0.03 |
| 12 | cis-β-ocimene | 1035 | 1032 | 0.7 ± 0.03 | 0.4 ± 0.05 | - | - |
| 13 | β-terpinene | 1040 | 1036 | - | 0.7 ± 0.03 | - | - |
| 14 | trans-β-ocimene | 1044 | 1043 | 0.3 ± 0.04 | - | - | - |
| 15 | γ-terpinene | 1059 | 1054 | 9.2 ± 0.04 | 2.7 ± 0.03 | 29.3 ± 0.03 | 1.1 ± 0.02 |
| 16 | cis-sabinene-hydrate | 1072 | 1069 | - | 5.0 ± 0.05 | - | - |
| 17 | terpinolene | 1079 | 1080 | - | - | 4.6 ± 0.04 | tr |
| 18 | linalool | 1090 | 1092 | 4.6 ± 0.02 | 3.9 ± 0.05 | - | - |
| 19 | terpinen-4-ol | 1164 | 1160 | 0.1 ± 0.02 | - | 10.2 ± 0.05 | - |
| 20 | estragole | 1180 | 1177 | - | 5.5 ± 0.06 | - | - |
| 21 | α-terpineol | 1185 | 1183 | - | - | 0.3 ± 0.04 | 0.2 ± 0.01 |
| 22 | anethole | 1269 | 1260 | - | 49.1 ± 0.05 | - | - |
| 23 | α-farnesene | 1510 | 1506 | - | 0.3 ± 0.02 | - | - |
| SUM | 100.0 | 99.9 | 100.0 | 100.0 | |||
| Terpenoids | 100.0 | 45.0 | 100.0 | 100.0 | |||
| Sesquiterpenoids | - | 0.3 | - | - | |||
| Other | - | 54.6 | - | - |
1 The components are reported according to their elution order on apolar column; 2 Linear Retention Indices measured on apolar column; 3 Linear Retention indices from the literature; 4 Percentage mean values of C. bergamia vapor phase components; 5 Percentage mean values of I. verum vapor phase components; 6 Percentage mean values of M. alternifolia vapor phase components; 7 Percentage mean values of E. globulus vapor phase components; - Not detected; tr: traces (mean value <0.1%).
Figure 1Cytopathic effect (CPE) induced by influenza virus treated with EOs vapor phases (PR8 + Bergamot; PR8 + TTO; PR8 + Eucalyptus; PR8 + Star Anise; PR8 + Anethole) or not treated (PR8 untreated) on MDCK cell monolayers analyzed by an inverted optical microscope after 24 h from infection. As control of infection, cells were mock-infected as described in methods.
Figure 2Cytotoxicity of EOs vapor phases. MDCK cell monolayers were treated with a mixture of PBS + EOs vapors and compared to cells incubated with PBS untreated (control). (A) Cell monolayers were observed by an inverted optical microscope or (B) evaluated by MTT assay. Cell viability was expressed as percentage (%) by comparison to control cells (considered as 100%). The values represent the mean ± S.D. of three technical replicates performed (n = 3).
Figure 3The expression of HA protein was analyzed on MDCK monolayers (left panel) by ICW assay using LI-COR Image Studio Software to measure the Relative Fluorescence Units (RFU) (right panel). The graph represents the percentage (%) of RFU calculated in cells infected with PR8 treated with different vapor EOs compared to that of PR8 untreated-infected cells (considered 100%). The values represent the mean ± S.D. of three technical replicates performed (n = 3). Statistical significance of data vs. PR8 untreated-infected cells was defined as * p < 0.05 and ** p < 0.001.
Figure 4Negative staining of IAV particles. Control virions (A), bergamot (B), TTO (C) or anethole (D) vapor phases exposed virions.